/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BioLine RX Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.22 0.0063(0.63%) BLRX at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 3.25
Highest Today 3.38
Today’s Open 3.38
Prev. Close 3.2
52 Week High 14.80
52 Week Low 2.30
Day’s Range: Low 3.25 High 3.38
52-Week Range: Low 2.30 High 14.80
1 day return -
1 Week return -8.78
1 month return -2.71
3 month return -9.29
6 month return -30.45
1 year return +1070.9
3 year return +347.22
5 year return +40.0
10 year return -

Institutional Holdings

Citadel Advisors Llc 0.35

SIMPLEX TRADING, LLC 0.33

TWO SIGMA SECURITIES, LLC 0.32

Susquehanna International Group, LLP 0.26

Rhumbline Advisers 0.10

Citigroup Inc 0.09

Wells Fargo & Co 0.04

Fidelity Nasdaq Composite Index 0.04

Morgan Stanley - Brokerage Accounts 0.04

Goss Wealth Management LLC 0.00

Fifth Third Bancorp 0.00

Advisor Group Holdings, Inc. 0.00

Bank of America Corp 0.00

BNP Paribas Arbitrage, SA 0.00

CapTrust Financial Advisors 0.00

Geneos Wealth Management Inc 0.00

Hibernia Wealth Partners LLC 0.00

SBI Securities Co Ltd 0.00

Values First Advisors Inc 0.00

Watts Gwilliam and Company, LLC 0.00

Weaver Consulting Group 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15.18 M

PB Ratio 0.7441

PE Ratio 0.0

Enterprise Value 0.59 M

Total Assets 38.91 M

Volume 14700

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-52461000 -52.5M, FY22:-18872000 -18.9M, FY21:-28144000 -28.1M, FY20:-30932000 -30.9M, FY19:-26806000 -26.8M

Quarterly Revenue Q3/2025:4943000 4.9M, Q2/2025:304000 0.3M, Q1/2025:255000 0.3M, Q3/2024:4943000 4.9M, Q2/2024:5393000 5.4M

Quarterly Profit Q3/2025:4121000 4.1M, Q2/2025:232000 0.2M, Q1/2025:221000 0.2M, Q3/2024:4121000 4.1M, Q2/2024:4496000 4.5M

Quarterly Net worth Q3/2025:-5822000 -5.8M, Q2/2025:-3940000 -3.9M, Q1/2025:5127000 5.1M, Q3/2024:-5822000 -5.8M, Q2/2024:484000 0.5M

Fund house & investment objective

Company Information BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Organisation Biotechnology

Employees 28

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow